{"id":33263,"date":"2023-07-31T10:16:23","date_gmt":"2023-07-31T08:16:23","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=33263"},"modified":"2023-08-24T10:19:42","modified_gmt":"2023-08-24T08:19:42","slug":"erganzende-schutzzertifikate-fur-arzneimittel-euzw-2023-643","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/cn\/publikationen\/erganzende-schutzzertifikate-fur-arzneimittel-euzw-2023-643\/","title":{"rendered":"Erg\u00e4nzende Schutzzertifikate f\u00fcr Arzneimittel, EuZW 2023, 643"},"content":{"rendered":"\n<p>On April 27, 2023, the European Commission presented four proposals for Regulations on supplementary protection certificates as part of the Intellectual Property Action Plan. In this article, <a href=\"https:\/\/www.maiwald.eu\/cn\/team\/gisela-grabow\/\">Dr Gisela Grabow<\/a>, together with Dr Bernadette Makoski LL.M., focuses on the two proposals for Regulations concerning supplementary protection certificates for medicinal products.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-33263","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/publikationen\/33263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/publikationen\/33263\/revisions"}],"predecessor-version":[{"id":33266,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/publikationen\/33263\/revisions\/33266"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=33263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}